Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy.

Journal of medical economics·2026
Same author

Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy.

Cancers·2026
Same author

The novel (TCTG)<sub>n</sub> motif in CNBP expanded alleles: composition, dynamics and genotype-phenotype correlation in Myotonic dystrophy type 2 (DM2).

Human genomics·2026
Same author

Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy.

European journal of human genetics : EJHG·2026
Same author

Unmasking Brugada ECG Pattern in Myotonic Dystrophy Type 2 With an ANK2 Variant.

Pacing and clinical electrophysiology : PACE·2026
Same author

A gene expression study suggests the possible involvement of IGF2BP2-related ncRNA network in Type 2 Diabetes.

Acta diabetologica·2026
Same journal

Brain-derived neurotrophic factor (BDNF) signaling in respiratory disease: Mechanisms, neuroimmune crosstalk, and therapeutic implications.

Pulmonary pharmacology & therapeutics·2026
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Related Experiment Videos

Biomarkers in COPD.

Mario Cazzola1, Giuseppe Novelli

  • 1Department of Internal Medicine, Respiratory Clinical Pharmacology Unit, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it

Pulmonary Pharmacology & Therapeutics
|May 18, 2010
PubMed
Summary
This summary is machine-generated.

Identifying reliable pulmonary biomarkers for Chronic Obstructive Pulmonary Disease (COPD) is crucial. Integrative functional informatics offers a novel approach to discover robust and reproducible COPD biomarkers for better disease management.

Related Experiment Videos

Area of Science:

  • Pulmonary medicine
  • Biomarker discovery
  • Integrative functional informatics

Background:

  • Increasing interest in pulmonary biomarkers for Chronic Obstructive Pulmonary Disease (COPD) assessment.
  • Limited data on biomarker reproducibility and correlation with clinical outcomes in COPD.
  • Need for validated biomarkers to monitor disease activity and predict therapeutic effects.

Purpose of the Study:

  • To highlight the need for robust and reproducible biomarkers in COPD.
  • To introduce integrative functional informatics as a novel approach for biomarker discovery in COPD.

Main Methods:

  • Review of current literature on pulmonary biomarkers in COPD.
  • Introduction of integrative functional informatics, combining genomics, proteomics, metabolomics, and pharmacogenetics.
  • Data collection and analysis through integrative approaches.

Main Results:

  • A significant gap exists in the understanding of COPD biomarker reproducibility and clinical correlation.
  • Integrative functional informatics presents a promising direction for biomarker identification.

Conclusions:

  • Robust, reliable, and reproducible biomarkers are essential for effective COPD management.
  • Integrative functional informatics holds the potential to identify such biomarkers, advancing COPD research and patient care.